The DOI matches its Crossref record; 67 of the 68 references it cites were found in a registry or an index.
Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration
Abstract
Because accumulation of alpha-synuclein (alphaS) in the brain is a hallmark of Parkinson disease (PD) and related disorders, we examined its occurrence in human cerebrospinal fluid (CSF). Following affinity enrichment and trypsin digestion of CSF collected from a neurologically healthy donor, we identified several alphaS-derived peptides by mass spectrometry. The concentration of alphaS amounted to <0.001% of the CSF proteome. We then built, validated and optimized a sandwich-type, enzyme-linked immunoadsorbent assay (ELISA) to measure total alphaS levels in unconcentrated CSF. In a cross-sectional study of 100 living donors, we examined cell-free CSF samples from subjects clinically diagnosed with advanced PD, dementia with Lewy bodies (DLB), Alzheimer disease (AD), and a group of non-neurodegenerative disease controls (NCO). In these four groups the CSF alphaS concentrations ranged from 0.8 to 16.2 pg/microl. Mean CSF alphaS values were lower in donors with a primary synucleinopathy (PD, DLB: n=57) than in the other two groups (AD, NCO: n=35; p=0.025). By contrast, living Creutzfeldt-Jakob disease patients showed markedly elevated CSF alphaS levels (n=8; mean, 300 pg/microl; p<0.001). Our results unequivocally confirm the presence of alphaS in adult human CSF. In a first feasibility study employing a novel ELISA, we found relatively low CSF alphaS concentrations in subjects with parkinsonism linked to synucleinopathy, PD and DLB. In definite prion disease cases, we recorded a marked rise in total CSF alphaS resulting from rapid cell death. Our results will likely aid future biomarker explorations in neurodegenerative conditions and facilitate target validation studies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“numerous studies have documented unaltered or slightly increased CSF αSyn levels in patients with MCI and AD [27, 80–82, 86, 90, 91, 93, 94].”
From α-synuclein in the pathophysiology of Alzheimer’s disease (2019) · cites this paper as [82]
Citations
Cites
1 retracted
Retracted: Dopamine receptor immunohistochemistry in the rat choroid plexus
Mignini, F., Bronzetti, E., Felici, L., Rícci, A., Sabbatini, M., Tayebati, S. K., & Amenta, F. (2000) · Journal of Autonomic Pharmacology · doi:10.1046/j.1365-2680.2000.00198.x · Cited by 25
RetractedMcKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960
Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy
Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., & Sulzer, D. (2004) · Science · doi:10.1126/science.1101738 · Cited by 2,024
Levodopa and the Progression of Parkinson's Disease
The Parkinson Study Group (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,844
Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System
Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.-H., Castillo, P. E., Shinsky, N., Verdugo, J. M. G., Armanini, M., Ryan, A., et al. (2000) · Neuron · doi:10.1016/s0896-6273(00)80886-7 · Cited by 1,722
Conway, K. A., Lee, S., Rochet, J., Ding, T. T., Williamson, R. E., & Lansbury, P. T. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.2.571 · Cited by 1,559
Anderson, J. P., Walker, D., Goldstein, J. M., de Laat, R., Banducci, K., Caccavello, R. J., Barbour, R., Huang, J., Kling, K., Lee, M., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600933200 · Cited by 1,452
Self-citationCSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897
Active Caspase-1 Is a Regulator of Unconventional Protein Secretion
Keller, M., Rüegg, A., Werner, S., & Beer, H. (2008) · Cell · doi:10.1016/j.cell.2007.12.040 · Cited by 851
Intravesicular Localization and Exocytosis of α-Synuclein and its Aggregates
Lee, H.-J., Patel, S. S., & Lee, S. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.0692-05.2005 · Cited by 824
Yeast Cells Provide Insight into Alpha-Synuclein Biology and Pathobiology
Outeiro, T. F., & Lindquist, S. L. (2003) · Science · doi:10.1126/science.1090439 · Cited by 811
Self-citationGenetics of Parkinson disease: paradigm shifts and future prospects
Farrer, M. J. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1831 · Cited by 724
El‐Agnaf, O. M. A., Salem, S. A., Paleologou, K. E., Curran, M. D., Gibson, M. J., Court, J. A., Schlossmacher, M. G., & Allsop, D. (2006) · The FASEB Journal · doi:10.1096/fj.03-1449com · Cited by 715
Self-citationReduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease
Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701
THE BIOCHEMISTRY OF PARKINSON'S DISEASE
Cookson, M. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.082803.133400 · Cited by 666
Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.673 · Cited by 660
Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M. (2006) · Nature Medicine · doi:10.1038/nm1438 · Cited by 599
El-Agnaf, O. M. A., Salem, S. A., Paleologou, K. E., Cooper, L. J., Fullwood, N. J., Gibson, M. J., Curran, M. D., Court, J. A., Mann, D. M. A., Ikeda, S.-I., et al. (2003) · The FASEB Journal · doi:10.1096/fj.03-0098fje · Cited by 590
Self-citationStefanis, L., Larsen, K. E., Rideout, H. J., Sulzer, D., & Greene, L. A. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-24-09549.2001 · Cited by 584
Kramer, M. L., & Schulz-Schaeffer, W. J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4564-06.2007 · Cited by 571
Self-citationRed Blood Cells Are the Major Source of Alpha-Synuclein in Blood
Barbour, R., Kling, K., Anderson, J. P., Banducci, K., Cole, T. A., Diep, L., Fox, M., Goldstein, J. M., Soriano, F., Seubert, P. A., et al. (2008) · Neurodegenerative Diseases · doi:10.1159/000112832 · Cited by 548
Molecular markers of early Parkinson's disease based on gene expression in blood
Scherzer, C. R., Eklund, A. C., Morse, L. J., Liao, Z., Locascio, J. J., Fefer, D., Schwarzschild, M. A., Schlossmacher, M. G., Hauser, M. A., Vance, J. M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610204104 · Cited by 518
Self-citationTokuda, T., Salem, S. A., Allsop, D., Mizuno, T., Nakagawa, M., Qureshi, M. M., Locascio, J. J., Schlossmacher, M. G., & El-Agnaf, O. M. A. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.08.024 · Cited by 425
Self-citationPhenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication
Fuchs, J., Nilsson, C., Kachergus, J. M., Munz, M., Larsson, E., Schüle, B., Langston, J. W., Middleton, F. A., Ross, O. A., Hulihan, M., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000254458.17630.c5 · Cited by 397
El‐Agnaf, O. M. A., Jakes, R., Curran, M. D., Middleton, D., Ingenito, R., Bianchi, E., Pessi, A., Neill, D., & Wallace, A. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01418-5 · Cited by 368
Self-citationα-Synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication
Miller, D. W., Hague, S., Clarimón, J., Baptista, M., Gwinn, K. A., Cookson, M., & Singleton, A. (2004) · Neurology · doi:10.1212/01.wnl.0000127517.33208.f4 · Cited by 356
Proteins in cerebrospinal fluid and blood: Barriers, CSF flow rate and source-related dynamics
Reiber, H. (2003) · Restorative Neurology and Neuroscience · doi:10.3233/rnn-2003-00229 · Cited by 354
Neuropathological spectrum of synucleinopathies
Jellinger, K. A. (2003) · Movement Disorders · doi:10.1002/mds.10557 · Cited by 345
Shin, Y., Klucken, J., Patterson, C., Hyman, B. T., & McLean, P. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503326200 · Cited by 335
Self-citationClinical heterogeneity of α‐synuclein gene duplication in Parkinson's disease
Nishioka, K., Hayashi, S., Farrer, M. J., Singleton, A., Yoshino, H., Imai, H., Kitami, T., Sato, K., Kuroda, R., Tomiyama, H., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20753 · Cited by 319
Aggregated α-Synuclein Mediates Dopaminergic Neurotoxicity In Vivo
Periquet, M., Fulga, T. A., Myllykangas, L., Schlossmacher, M. G., & Feany, M. Β. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0285-07.2007 · Cited by 299
Self-citationTau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt–Jakob disease
Otto, M., Wiltfang, J., Cepek, L., Neumann, M., Mollenhauer, B., Steinacker, P., Ciesielczyk, B., Schulz‐Schaeffer, W., Kretzschmar, H. A., & Poser, S. (2002) · Neurology · doi:10.1212/wnl.58.2.192 · Cited by 287
Self-citationShtilerman, M. D., Ding, T. T., & Lansbury, P. T. (2002) · Biochemistry · doi:10.1021/bi0120906 · Cited by 280
Genetic variability in the SNCA gene influences α‐synuclein levels in the blood and brain
Fuchs, J., Tichopád, A., Golub, Y., Munz, M., Schweitzer, K. J., Wolf, B., Berg, D., Mueller, J. C., & Gasser, T. (2007) · The FASEB Journal · doi:10.1096/fj.07-9348com · Cited by 254
Development of the choroid plexus
Dzięgielewska, K. M., Ek, C. J., Habgood, M. D., & Saunders, N. R. (2000) · Microscopy Research and Technique · doi:10.1002/1097-0029(20010101)52:1 · Cited by 245
Multiple-system atrophy: a new α-synuclein disease?
Gai, W., Power, J., Blumbergs, P. C., & Blessing, W. W. (1998) · The Lancet · doi:10.1016/s0140-6736(05)79256-4 · Cited by 231
Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer’s disease
Grossman, M., Farmer, J., Leight, S., Work, M., Moore, P., Van Deerlin, V., Pratico, D., Clark, C. M., Coslett, H. B., Chatterjee, A., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20477 · Cited by 228
Bibl, M., Mollenhauer, B., Esselmann, H., Lewczuk, P., Klafki, H., Sparbier, K., Av, S., Cepek, L., Trenkwalder, C., Rüther, E., et al. (2006) · Brain · doi:10.1093/brain/awl063 · Cited by 212
Self-citationIn vivo alpha-synuclein overexpression in rodents: A useful model of Parkinson's disease?
Chesselet, M. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.08.006 · Cited by 193
Biomarkers and Parkinson's disease
Michell, A. W. (2004) · Brain · doi:10.1093/brain/awh198 · Cited by 182
Cell systems and the toxic mechanism(s) of α-synuclein
Cookson, M., & van der Brug, M. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.05.022 · Cited by 177
The genetics of Parkinson disease: implications for neurological care
Klein, C., & Schlossmacher, M. G. (2006) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0126 · Cited by 169
Self-citationPlasma α-synuclein is decreased in subjects with Parkinson's disease
Li, Q., Mok, S. S., Laughton, K. M., McLean, C., Cappai, R., Masters, C. L., Culvenor, J. G., & Horne, M. K. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.12.006 · Cited by 161
Lewczuk, P., Beck, G., Esselmann, H., Bruckmoser, R., Zimmermann, R., Fiszer, M., Bibl, M., Maler, J. M., Kornhuber, J., & Wiltfang, J. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2005.058776 · Cited by 146
Rimm, D. L. (2006) · Nature Biotechnology · doi:10.1038/nbt0806-914 · Cited by 139
Mollenhauer, B., Trenkwalder, C., von Ahsen, N., Bibl, M., Steinacker, P., Brechlin, P., Schindehütte, J., Poser, S., Wiltfang, J., & Otto, M. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000094871 · Cited by 132
Self-citationBiomarker method validation in anticancer drug development
Cummings, J., Ward, T. H., Greystoke, A., Ranson, M., & Dive, C. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707441 · Cited by 131
Accuracy in the clinical diagnosis of parkinsonian syndromes
Gibb, W. R. G. (1988) · Postgraduate Medical Journal · doi:10.1136/pgmj.64.751.345 · Cited by 100
Wadsworth, J. D. F. (2006) · Brain · doi:10.1093/brain/awl076 · Cited by 99
Mollenhauer, B., Cepek, L., Bibl, M., Wiltfang, J., Schulz‐Schaeffer, W., Ciesielczyk, B., Neumann, M., Steinacker, P., Kretzschmar, H. A., Poser, S., et al. (2005) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000083178 · Cited by 85
Self-citationMollenhauer, B., Bibl, M., Wiltfang, J., Steinacker, P., Ciesielczyk, B., Neubert, K., Trenkwalder, C., & Otto, M. (2006) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2006.035 · Cited by 76
Self-citationMollenhauer, B., Bibl, M., Trenkwalder, C., Stiens, G., Cepek, L., Steinacker, P., Ciesielczyk, B., Neubert, K., Wiltfang, J., Kretzschmar, H. A., et al. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0235-7 · Cited by 68
Self-citationPlatelet α- and γ-synucleins in Parkinson's disease and normal control subjects
Li, Q.-X., Campbell, B. C. V., McLean, C., Thyagarajan, D., Gai, W.-P., Kapsa, R. M. I., Beyreuther, K. T., Masters, C. L., & Culvenor, J. G. (2002) · Journal of Alzheimer s Disease · doi:10.3233/jad-2002-4406 · Cited by 49
Human-based studies on α-synuclein deposition and relationship to Parkinson's disease symptoms
Halliday, G. M., & McCann, H. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.07.006 · Cited by 48
Determination of α‐synuclein concentration in human plasma using ELISA
Fjorback, W. A., Varming, K., & Jensen, H. P. (2007) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510601161497 · Cited by 46
van Geel, W. J. A., Abdo, W. F., Melis, R. J. F., Williams, S., Bloem, B. R., & Verbeek, M. M. (2007) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2007.09.021 · Cited by 32
Biomarkers in Parkinson’s disease
Dorsey, E. R., Holloway, R. G., & Ravina, B. M. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.6.823 · Cited by 23
Diagnostic problems during late course in Creutzfeldt-Jakob disease
Mollenhauer, B., Serafin, S., Zerr, I., Steinhoff, B. J., Otto, M., Scherer, M., Schulz‐Schaeffer, W., & Poser, S. (2003) · Journal of Neurology · doi:10.1007/s00415-003-1059-3 · Cited by 20
Self-citationParkinson's Disease: Assays for the Ubiquitin Ligase Activity of Neural Parkin
Schlossmacher, M. G., & Shimura, H. (2005) · Humana Press eBooks · doi:10.1385/1-59259-895-1:351 · Cited by 19
Self-citation
Research works printed but not linked: 2
- Mollenhauer, 2006, Proteome analysis of cerebrospinal fluid by mass spectrometry: a platform for marker development in synucleinopathies, Movement Disorders, 21
- Schlossmacher, 2006, Monitoring of alpha-synuclein steady-state levels in vivo by ELISA, Movement disorders, 21
Cited by
Sorted by citations
-Synuclein in Parkinson's Disease
Stefanis, L. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009399 · Cited by 1,446
Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies
Irwin, D. J., Lee, V. M. ‐., & Trojanowski, J. Q. (2013) · Nature reviews. Neuroscience · doi:10.1038/nrn3549 · Cited by 914
Exosomal cell-to-cell transmission of alpha synuclein oligomers
Danzer, K. M., Kranich, L. R., Ruf, W. P., Cagsal‐Getkin, O., Winslow, A. R., Zhu, L., Vanderburg, C. R., & McLean, P. J. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-42 · Cited by 880
Self-citationMcKeith, I. G. (2004) · Europe PMC (PubMed Central) · Cited by 756
Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease
Shi, M., Liu, C., Cook, T. J., Bullock, K. M., Zhao, Y., Ginghina, C., Li, Y., Aro, P., Dator, R., He, C., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1314-y · Cited by 676
Metadata
- Authors
- Mollenhauer, B., Cullen, V., Kahn, I., Krastins, B., Outeiro, T. F., Pepivani, I., Ng, J., Schulz-Schaeffer, W., Kretzschmar, H. A., McLean, P. J., Trenkwalder, C., Sarracino, D. A., VonSattel, J.-P., Locascio, J. J., El-Agnaf, O. M. A., & Schlossmacher, M. G.
- Affiliations
- Brigham and Women's Hospital (US)
- Harvard University (US)
- University of Ottawa (CA)
- Ludwig-Maximilians-Universität München (DE)
- Paracelsus Elena Klinik Kassel (DE)
- Columbia University (US)
- Corresponding author
- Schlossmacher, Michael G.
- ORCID
- Venue
- Experimental Neurology
- Publisher
- Elsevier BV
- Published
- 2008-10
- Volume
- 213
- Issue
- 2
- Pages
- 315-325
- ISSN
- 0014-4886 (ISSN-L)
- OpenAlex
- W2003260773
- Cited by
- 382
- References
- 68
- Citations by year
- 2026: 6 · 2025: 18 · 2024: 8 · 2023: 9 · 2022: 22 · 2021: 16 · 2020: 25 · 2019: 19 · 2018: 16 · 2017: 17 · 2016: 20 · 2015: 25 · 2014: 32 · 2013: 26 · 2012: 30
- FWCI
- 19.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Experimental Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke (P50NS038375, 5P50-NS038375)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- alpha-synuclein, cerebrospinal fluid, Parkinson's disease, dementia with Lewy bodies, Alzheimer's disease, Creutzfeldt-Jakob disease, synucleinopathies, cell-free biomarkers, ELISA quantification, neurodegeneration, prion disease, cell death
- MeSH terms
- Adult, Aged, Aged, 80 and over, Amino Acid Sequence, Animals, Cells, Cultured, Cross-Sectional Studies, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Middle Aged, Molecular Sequence Data, Nerve Degeneration, Biomarkers, Mice, Rats, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
